Skip to main content

IPF

8
Pipeline Programs
9
Companies
6
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
5
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
2 programs
1
1
AMB-05XPhase 2
HW252001Phase 11 trial
Active Trials
NCT07493031Not Yet Recruiting98Est. Dec 2026
Orion Pharma
Orion PharmaUK - Reading
1 program
1
RXC007Phase 2
Orion
OrionUK - Cambridge
1 program
1
RXC007Phase 21 trial
Active Trials
NCT05570058Active Not Recruiting48Est. Jan 2025
Redx Pharma
Redx PharmaUK - Macclesfield
1 program
1
RXC007Phase 2
SPARK Biopharma
SPARK BiopharmaKorea - Seoul
1 program
1
SB17170Phase 21 trial
Active Trials
NCT06747923Recruiting30Est. Oct 2026
Agomab Therapeutics
Agomab TherapeuticsBelgium - Antwerpen
1 program
1
AGMB-447Phase 11 trial
Active Trials
NCT06181370Recruiting145Est. Jun 2026
Henovcom Bioscience
Henovcom BioscienceChina - Guangzhou
1 program
1
HNC1058 CapsulesPhase 11 trial
Active Trials
NCT05803850Completed32Est. Mar 2024
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Sample collectionN/A
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Sample collectionN/A1 trial
Active Trials
NCT04564183Active Not Recruiting800Est. Aug 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SPARK BiopharmaSB17170
OrionRXC007
BiocorpHW252001
Agomab TherapeuticsAGMB-447
Henovcom BioscienceHNC1058 Capsules
Colorado TherapeuticsSample collection

Clinical Trials (6)

Total enrollment: 1,153 patients across 6 trials

SB17170 Phase 2 Trial in IPF Patients

Start: Jan 2025Est. completion: Oct 202630 patients
Phase 2Recruiting

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Start: Sep 2022Est. completion: Jan 202548 patients
Phase 2Active Not Recruiting

A PhaseⅠ Study of HW252001 in Healthy Subjects

Start: Mar 2026Est. completion: Dec 202698 patients
Phase 1Not Yet Recruiting

Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

Start: Dec 2023Est. completion: Jun 2026145 patients
Phase 1Recruiting

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

Start: Mar 2023Est. completion: Mar 202432 patients
Phase 1Completed

Advancing Prevention of Pulmonary Fibrosis

Start: Jan 2021Est. completion: Aug 2026800 patients
N/AActive Not Recruiting

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 1,153 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.